Trial | NCT00960479  Report issue

Title

Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Fasting Conditions
A Relative Bioavailability Study of Ribavirin (Geneva Pharmaceutical Technology Corporation, N.J., U.S.A.) 200 Capsules and Rebetol (Schering Corporation, N.J., U.S.A.) 200 mg Capsules in Females Under Fasting Conditions.

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    ribavirin ...

  • Study Participants

    38
The purpose of this study is to demonstrate the relative bioavailability of Ribavirin 200 capsules and Rebetol 200 mg capsules in females under fasting conditions.
Study Started
Jan 31
2001
Primary Completion
Feb 28
2001
Study Completion
Feb 28
2001
Last Update
Mar 28
2017

Drug Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)

Drug Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)

1 Experimental

Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)

2 Active Comparator

Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)

Criteria 

Inclusion Criteria:

No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria:

Positive test results for HIV or hepatitis B or C.
Treatment for drug or alcohol dependence.
No Results Posted